1. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression.
- Author
-
Sirpilla O, Sakemura RL, Hefazi M, Huynh TN, Can I, Girsch JH, Tapper EE, Cox MJ, Schick KJ, Manriquez-Roman C, Yun K, Stewart CM, Ogbodo EJ, Kimball BL, Mai LK, Gutierrez-Ruiz OL, Rodriguez ML, Gluscevic M, Larson DP, Abel AM, Wierson WA, Olivier G, Siegler EL, and Kenderian SS
- Subjects
- Animals, Mice, Humans, Mesenchymal Stem Cell Transplantation methods, T-Lymphocytes immunology, Cadherins metabolism, Mice, Inbred C57BL, Cytokines metabolism, Mesenchymal Stem Cells immunology, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells metabolism, Immunosuppression Therapy methods, Receptors, Chimeric Antigen metabolism, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen genetics, Graft vs Host Disease immunology
- Abstract
Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment option for many disorders of the immune system. However, clinical trials using MSCs have shown inconsistent therapeutic efficacy, mostly owing to MSCs providing insufficient immunosuppression in target tissues. Here we show that antigen-specific immunosuppression can be enhanced by genetically modifying MSCs with chimaeric antigen receptors (CARs), as we show for E-cadherin-targeted CAR-MSCs for the treatment of graft-versus-host disease in mice. CAR-MSCs led to superior T-cell suppression and localization to E-cadherin
+ colonic cells, ameliorating the animals' symptoms and survival rates. On antigen-specific stimulation, CAR-MSCs upregulated the expression of immunosuppressive genes and receptors for T-cell inhibition as well as the production of immunosuppressive cytokines while maintaining their stem cell phenotype and safety profile in the animal models. CAR-MSCs may represent a widely applicable therapeutic technology for enhancing immunosuppression., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2024
- Full Text
- View/download PDF